phosphorylcholine has been researched along with Coronary Artery Stenosis in 8 studies
Phosphorylcholine: Calcium and magnesium salts used therapeutically in hepatobiliary dysfunction.
phosphocholine : The phosphate of choline; and the parent compound of the phosphocholine family.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Low anti-phosphorylcholine (PC) IgM plasma levels have been associated with increased incidence of adverse events in coronary artery disease (CAD)." | 7.81 | Low levels of natural IgM antibodies against phosphorylcholine are independently associated with vascular remodeling in patients with coronary artery disease. ( Akhavanpoor, M; Buss, SJ; Conradson, G; Doesch, AO; Domschke, G; Erbel, C; Gitsioudis, G; Gleissner, CA; Haeussler, J; Hofmann, NP; Katus, HA; Korosoglou, G; Linden, F, 2015) |
| "Patients (n =1,197) treated for single coronary artery stenosis were enrolled in a prospective, randomized, double-blind study and randomly assigned to receive the Endeavor zotarolimus-eluting phosphorylcholine polymer-coated stent (n= 598) or the same bare metal stent but without the drug or the polymer coating (n=599)." | 5.12 | Randomized, double-blind, multicenter study of the Endeavor zotarolimus-eluting phosphorylcholine-encapsulated stent for treatment of native coronary artery lesions. Clinical and angiographic results of the ENDEAVOR II Trial. ( Bonan, R; Fajadet, J; Fitzgerald, PJ; Kuck, KH; Kuntz, RE; Laarman, GJ; Münzel, T; Ormiston, J; Popma, JJ; Wijns, W, 2007) |
| "Low anti-phosphorylcholine (PC) IgM plasma levels have been associated with increased incidence of adverse events in coronary artery disease (CAD)." | 3.81 | Low levels of natural IgM antibodies against phosphorylcholine are independently associated with vascular remodeling in patients with coronary artery disease. ( Akhavanpoor, M; Buss, SJ; Conradson, G; Doesch, AO; Domschke, G; Erbel, C; Gitsioudis, G; Gleissner, CA; Haeussler, J; Hofmann, NP; Katus, HA; Korosoglou, G; Linden, F, 2015) |
| "Zotarolimus is a recently developed pharmacologic agent with both antiproliferative and anti-inflammatory properties." | 2.43 | Overview of pharmacology and clinical trials program with the zotarolimus-eluting endeavor stent. ( Kandzari, DE; Leon, MB, 2006) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (12.50) | 18.2507 |
| 2000's | 6 (75.00) | 29.6817 |
| 2010's | 1 (12.50) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Gleissner, CA | 1 |
| Erbel, C | 1 |
| Haeussler, J | 1 |
| Akhavanpoor, M | 1 |
| Domschke, G | 1 |
| Linden, F | 1 |
| Doesch, AO | 1 |
| Conradson, G | 1 |
| Buss, SJ | 1 |
| Hofmann, NP | 1 |
| Gitsioudis, G | 1 |
| Katus, HA | 1 |
| Korosoglou, G | 1 |
| Bakhai, A | 1 |
| Booth, J | 1 |
| Delahunty, N | 1 |
| Nugara, F | 1 |
| Clayton, T | 1 |
| McNeill, J | 1 |
| Davies, SW | 1 |
| Cumberland, DC | 1 |
| Stables, RH | 1 |
| Kandzari, DE | 1 |
| Leon, MB | 1 |
| Fajadet, J | 1 |
| Wijns, W | 1 |
| Laarman, GJ | 1 |
| Kuck, KH | 1 |
| Ormiston, J | 1 |
| Münzel, T | 1 |
| Popma, JJ | 2 |
| Fitzgerald, PJ | 2 |
| Bonan, R | 1 |
| Kuntz, RE | 1 |
| Dubé, H | 1 |
| Clifford, AG | 1 |
| Barry, CM | 1 |
| Schwarten, DE | 1 |
| Schwartz, LB | 3 |
| Abizaid, A | 3 |
| Lansky, AJ | 1 |
| Tanajura, LF | 2 |
| Feres, F | 2 |
| Staico, R | 1 |
| Mattos, L | 1 |
| Chaves, A | 1 |
| Centemero, M | 1 |
| Sousa, AG | 1 |
| Sousa, JE | 1 |
| Zaugg, MJ | 1 |
| Hattori, K | 1 |
| Solberg, B | 1 |
| Larracas, C | 1 |
| Costa, Jde R | 1 |
| Zheng, H | 1 |
| Barragan, P | 1 |
| Corcos, T | 1 |
| Siméoni, JB | 1 |
| Favereau, X | 1 |
| Roquebert, PO | 1 |
| Guérin, Y | 1 |
| Sainsous, J | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Prospective, Multi-Center, Non-Randomized, Single-Arm Trial to Evaluate the Safety and Feasibility of the TriMaxx Coronary Stent in de Novo Coronary Artery Lesions.[NCT00596661] | Phase 1 | 100 participants (Actual) | Interventional | 2004-05-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
1 review available for phosphorylcholine and Coronary Artery Stenosis
| Article | Year |
|---|---|
Overview of pharmacology and clinical trials program with the zotarolimus-eluting endeavor stent.
Topics: Anti-Inflammatory Agents; Blood Vessel Prosthesis Implantation; Clinical Trials as Topic; Coated Mat | 2006 |
3 trials available for phosphorylcholine and Coronary Artery Stenosis
| Article | Year |
|---|---|
The SV stent study: a prospective, multicentre, angiographic evaluation of the BiodivYsio phosphorylcholine coated small vessel stent in small coronary vessels.
Topics: Adult; Aged; Aged, 80 and over; Angioplasty, Balloon, Coronary; Coated Materials, Biocompatible; Cor | 2005 |
Randomized, double-blind, multicenter study of the Endeavor zotarolimus-eluting phosphorylcholine-encapsulated stent for treatment of native coronary artery lesions. Clinical and angiographic results of the ENDEAVOR II Trial.
Topics: Aged; Australia; Cardiovascular Agents; Coronary Angiography; Coronary Restenosis; Coronary Stenosis | 2007 |
Percutaneous coronary revascularization using a trilayer metal phosphorylcholine-coated zotarolimus-eluting stent.
Topics: Aged; Angioplasty, Balloon, Coronary; Blood Vessel Prosthesis Implantation; Cardiovascular Agents; C | 2007 |
4 other studies available for phosphorylcholine and Coronary Artery Stenosis
| Article | Year |
|---|---|
Low levels of natural IgM antibodies against phosphorylcholine are independently associated with vascular remodeling in patients with coronary artery disease.
Topics: Aged; Autoantibodies; Biomarkers; Chi-Square Distribution; Coronary Angiography; Coronary Artery Dis | 2015 |
Comparison of the vascular responses to balloon-expandable stenting in the coronary and peripheral circulations: long-term results in an animal model using the TriMaxx stent.
Topics: Angioplasty, Balloon; Angioplasty, Balloon, Coronary; Animals; Arterial Occlusive Diseases; Coated M | 2007 |
Clinical and angiographic results of percutaneous coronary revascularization using a trilayer stainless steel-tantalum-stainless steel phosphorylcholine-coated stent: the TriMaxx trial.
Topics: Aged; Angioplasty, Balloon, Coronary; Brazil; Cardiovascular Agents; Cardiovascular Diseases; Corona | 2007 |
Clinical experience with a new biocompatible phosphorylcholine-coated coronary stent.
Topics: Adult; Aged; Aged, 80 and over; Angioplasty, Balloon, Coronary; Blood Vessel Prosthesis; Blood Vesse | 1999 |